CB-13 - CAS 432047-72-8
Catalog number:
432047-72-8
Category:
Inhibitor
Not Intended for Therapeutic Use. For research use only.
Molecular Formula:
C26H24O2
Molecular Weight:
368.47
COA:
Inquire
Targets:
Cannabinoid Receptor
Description:
CB-13 is a dual agonist of the CB1 (IC50 = 15 nM) and CB2 (IC50 = 98 nM) receptors, displays antihyperalgesic activity in a rat model of neuropathic pain with no CNS side effects.
Publictions citing BOC Sciences Products
  • >> More
Purity:
≥95%
Appearance:
Solid powder
Synonyms:
1-Naphthalenyl[4-(pentyloxy)-1-naphthalenyl]methanone;
Solubility:
Soluble in DMSO
Storage:
Store at -20 °C
MSDS:
Inquire
Application:
Potent, orally active CB1/CB2 receptor agonist with limited brain penetration
Quality Standard:
Enterprise standard
Shelf Life:
As supplied, 2 years from the QC date provided on the Certificate of Analysis, when stored properly.
Quantity:
Milligrams-Grams
InChIKey:
RSUMDJRTAFBISX-UHFFFAOYSA-N
InChI:
1S/C26H24O2/c1-2-3-8-18-28-25-17-16-24(21-13-6-7-14-22(21)25)26(27)23-15-9-11-19-10-4-5-12-20(19)23/h4-7,9-17H,2-3,8,18H2,1H3
Canonical SMILES:
CCCCCOC1=CC=C(C2=CC=CC=C21)C(=O)C3=CC=CC4=CC=CC=C43
Current Developer:
Novatis
1.Development and validation of an RP-HPLC method for CB13 evaluation in several PLGA nanoparticle systems.
Alvarez-Fuentes J1, Martín-Banderas L, Muñoz-Rubio I, Holgado MA, Fernández-Arévalo M. ScientificWorldJournal. 2012;2012:737526. doi: 10.1100/2012/737526. Epub 2012 Jun 18.
A simple, fast, and reversed-phase high-performance liquid chromatographic (RP-HPLC) method has been developed and validated for determining of a cannabinoid derivate, which displays potent antihyperalgesic activity, 1-naphthalenyl[4-(pentyloxy)-1-naphthalenyl]methanone (CB13) into PLGA nanoparticles. Separation was achieved in a C18 column using a mobile phase consisting of two solvents: solvent A, consisting of acetonitrile : water : acetic acid (75 : 23.7 : 1.3 v/v), and solvent B, consisting of acetonitrile. An isocratic method (70 : 30 v/v), with a flow rate of 1.000 mL/min, and a diode array detector were used. The developed method was precise, accurate, and linear over the concentration range of analysis with a limit of detection and a limit of quantification of 0.5 and 1.25 μg/mL, respectively. The developed method was applied to the analysis of CB13 in nanoparticles samples obtained by three different procedures (SEV, FF, and NPP) in terms of encapsulation efficiency and drug release.
2.The anti-nausea effects of CB1 agonists are mediated by an action at the visceral insular cortex.
Limebeer CL1, Rock EM, Mechoulam R, Parker LA. Br J Pharmacol. 2012 Nov;167(5):1126-36. doi: 10.1111/j.1476-5381.2012.02066.x.
BACKGROUND AND PURPOSE: Conditioned gaping reactions reflect nausea-induced behaviour in rats. Cannabinoid 1 receptor (CB(1) ) agonists interfere with the establishment of nausea-induced conditioned gaping; however, it is not known if their effects are mediated by an action at peripheral or central CB(1) receptors.
3.Cannabinoid derivate-loaded PLGA nanocarriers for oral administration: formulation, characterization, and cytotoxicity studies.
Martín-Banderas L1, Alvarez-Fuentes J, Durán-Lobato M, Prados J, Melguizo C, Fernández-Arévalo M, Holgado MÁ. Int J Nanomedicine. 2012;7:5793-806. doi: 10.2147/IJN.S34633. Epub 2012 Nov 23.
CB13 (1-Naphthalenyl[4-(pentyloxy)-1-naphthalenyl]methanone)-loaded poly(lactic-co-glycolic acid) nanoparticles (NPs) were produced by nanoprecipitation and tested for their in vitro release behavior and in vitro cytotoxicity assays. The effects of several formulation parameters such as polymer type, surfactant concentration, and initial drug amount were studied. NPs had a particle size 90-300 nm in diameter. Results obtained show that the main influence on particle size was the type of polymer employed during the particle production: the greater the hydrophobicity, the smaller the particle size. In terms of encapsulation efficiency (%), high values were achieved (∼68%-90%) for all formulations prepared due to the poor solubility of CB13 in the external aqueous phase. Moreover, an inverse relationship between release rate and NP size was found. On the other hand, low molecular weight and low lactide content resulted in a less hydrophobic polymer with increased rates of water absorption, hydrolysis, and erosion.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Cannabinoid Receptor Products


CAS 168273-06-1 Rimonabant

Rimonabant
(CAS: 168273-06-1)

Rimonabant is a selective antagonist of CB1 with IC50 of 13.6 nM and EC50 of 17.3 nM in hCB1 transfected HEK 293 membrane.

CAS 1446-61-3 Leelamine

Leelamine
(CAS: 1446-61-3)

Leelamine, a diterpene molecule, has weak affinity for the human central cannabinoid (CB1) and peripheral cannabinoid (CB2) receptors. Leelamine is also a PDK(p...

CAS 406205-74-1 BAY 59-3074

BAY 59-3074
(CAS: 406205-74-1)

Bay 59-3074 is a novel, selective CB1/CB2 receptor partial agonist(Ki values are 48.3 and 45.5 nM at human CB1 and CB2 receptors respectively).

AM-1220
(CAS: 134959-64-1)

AM-1220 is a selective cannabinoid receptor CB1 agonist , with about 19x selectivity for CB1 over the related CB2 receptor originated by Sterling Winthrop. In O...

CAS 220556-69-4 ACEA

ACEA
(CAS: 220556-69-4)

ACEA is a selective cannabinoid receptor 1 (CB1R) agonist (Ki = 1.4 nM) with much higher affinity over CB2R. CB1 receptors are mainly expressed in the central a...

CB1-IN-1
(CAS: 1429239-98-4)

CB1-IN-1 is an antagonist of cannabinoid receptor type 1 (CB1R) located in the peripheral nervous system, which may be significant for pain modulation.

Levonantradol hydrochloride
(CAS: 70222-86-5)

Levonantrado is a synthetic cannabinoid analog of dronabinol developed by Pfizer in the 1980s. Levonantrado is around 30x more potent than THC, and exhibits ant...

CAS 868273-06-7 ORG-27569

ORG-27569
(CAS: 868273-06-7)

Org 27569 is an allosteric modulator of cannabinoid CB1 receptor, induces a CB1 receptor state that is characterized by enhanced agonist affinity and decreased ...

CAS 686344-29-6 Otenabant (CP-945,598)

Otenabant (CP-945,598)
(CAS: 686344-29-6)

Otenabant, also known as CP-945,598, is a drug which acts as a potent and highly selective CB1 antagonist. It was developed by Pfizer for the treatment of obesi...

CAS 432047-72-8 CB-13

CB-13
(CAS: 432047-72-8)

CB-13 is a dual agonist of the CB1 (IC50 = 15 nM) and CB2 (IC50 = 98 nM) receptors, displays antihyperalgesic activity in a rat model of neuropathic pain with n...

CAS 180002-83-9 L-768242

L-768242
(CAS: 180002-83-9)

L-768242, an indole derivative, has been found to be a CB2 receptor agonist and was once studied to exhibit anti-nociceptive and antihyperalgesic activities in ...

AM 1714
(CAS: 335371-37-4)

AM 1714, a synthetic cannabimimetic indole derivative, is a potent and selective agonist for the cannabinoid receptor.

CAS 871819-90-8 GSK554418A

GSK554418A
(CAS: 871819-90-8)

GSK-554418A is a azaindole Cannabinoid receptor type 2 (CB2) agonist. It can be used for the treatment of chronic pain.

CAS 131543-23-2 WIN 55212-2 mesylate

WIN 55212-2 mesylate
(CAS: 131543-23-2)

The mesylate salt form of WIN 55212-2, an aminoalkylindole derivative, is a CB receptor agonist and could be effective against some inflammatory reponse. IC50: ...

CAS 335160-66-2 AM 1248

AM 1248
(CAS: 335160-66-2)

AM1248 is an adamantoylindole derivative acts as a moderately potent agonist for both the cannabinoid receptors CB1 and CB2.

CAS 464213-10-3 Ibipinabant

Ibipinabant
(CAS: 464213-10-3)

Ibipinabant is a potent and selective CB1 receptor antagonist with Ki values of 7.8 and 7,943 nM for CB1 and peripheral cannabinoid (CB2), respectively.

CAS 701977-09-5 Taranabant

Taranabant
(CAS: 701977-09-5)

Taranabant is a cannabinoid 1 receptor inverse agonist ( IC50 =0.3 nM).

CAS 686347-12-6 Otenabant HCl

Otenabant HCl
(CAS: 686347-12-6)

Otenabant HCl is a selective and high affinity antagonist of CB1 with Ki value of 0.7 nM.

CAS 183232-66-8 AM251

AM251
(CAS: 183232-66-8)

AM251 block the inhibitory effects of endocannabinoids and synthetic cannabinoid agonists on transmitter release through an action at presynaptic cannabinoid 1 ...

CAS 959746-77-1 A-836339

A-836339
(CAS: 959746-77-1)

A-836339 is a synthetic and potent cannabinoid receptor full agonist. It displays a higher affinity for the peripheral CB2 receptor with Ki value of 0.64 nM ove...

Chemical Structure

CAS 432047-72-8 CB-13

Quick Inquiry

Verification code

Featured Items